PRECISION BIOSCIENCES INC
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
DTIL$10.60+7.4%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(In thousands, except share and per share amounts)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $137,766 | $116,678 |
| Accounts receivable | 390 | 901 |
| Prepaid expenses | 9,254 | 5,977 |
| Convertible note receivable | 11,553 | 11,897 |
| Assets held for sale | 378 | 487 |
| Contract asset | 1,359 | — |
| Other current assets | 128 | 419 |
| Total current assets | 160,828 | 136,359 |
| Property, equipment, and software—net | 5,286 | 6,338 |
| Intangible assets—net | 386 | 400 |
| Right-of-use assets—net | 7,979 | 8,263 |
| Investment in equity securities | 3,206 | 3,206 |
| Note receivable—net | 6,818 | 4,990 |
| Other assets | 238 | 225 |
| Total assets | $184,741 | $159,781 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $1,136 | $2,968 |
| Accrued compensation | 1,220 | 4,978 |
| Accrued research and development expenses | 656 | 1,557 |
| Deferred revenue | 2,406 | 12,035 |
| Loan payable-net | 22,460 | 22,412 |
| Lease liabilities | 1,182 | 1,133 |
| Other current liabilities | 2,772 | 2,391 |
| Current liabilities of discontinued operations | 1,506 | 2,513 |
| Total current liabilities | 33,338 | 49,987 |
| Deferred revenue | 74,766 | 73,082 |
| Lease liabilities | 7,411 | 7,723 |
| Warrant liability | 22,020 | — |
| Contract liabilities | 10,000 | 10,000 |
| Noncurrent liabilities of discontinued operations | — | 128 |
| Total liabilities | 147,535 | 140,920 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value— 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock: $0.000005 par value— 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 6,943,254 shares issued and 6,916,239 shares outstanding as of March 31, 2024; 4,191,053 shares issued and 4,164,038 shares outstanding as of December 31, 2023 | 1 | 1 |
| Additional paid-in capital | 519,200 | 509,443 |
| Accumulated deficit | (481,043) | (489,631) |
| Treasury stock | (952) | (952) |
| Total stockholders’ equity | 37,206 | 18,861 |
| Total liabilities and stockholders’ equity | $184,741 | $159,781 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.